Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 1;32(1):11–25. doi: 10.3904/kjim.2016.174

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Potential therapeutic effects of sodium/glucose co-transporter 2 (SGLT2) inhibition in diabetic nephropathy. Decreased proximal tubular glucose reabsorption with SGLT2 inhibition results in reduced glomerular hyperfiltration and hypertension with further reduction in albuminuria. Increased sodium delivery to the macula densa modulates tubuloglomerular feedback and contributes to decreased blood pressure, intravascular volume, and arterial stiffness. Metabolic effects of SGLT2 inhibition include reduced glycated hemoglobin (HbA1c), inflammation and weight loss. GLUT2, glucose transporter 2.